| 摘要 |
The disclosure relates to the use of heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) kinase activity for treatment of proliferative disorders. Selectivity in inhibition of various mutant-EGFR is disclosed. Pharmaceutical compositions containing the pyrimidine derivatives, and methods of treating diseases associated with EGFR kinase activity comprising administration of the pyrimidine derivatives or pharmaceutical compositions containing the pyrimidine derivative, are described. Intermediates in the synthesis of the compounds are also disclosed. The proliferative disorder may in particular be one of breast cancer, glioblastoma, lung cancer, cancer of the head and neck, colorectal cancer, and bladder cancer. |
